Efficacy of Aconiti tuber for chemotherapy‐induced peripheral neuropathy with peripheral coldness and/or symptoms relief by warming: A case series

2021 ◽  
Author(s):  
Tatsuto Terada ◽  
Tomofumi Miura ◽  
Kazuhiro Kosugi ◽  
Maika Natsume ◽  
Midori Y. Yajima ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Case Series

scholarly journals T118M Variant of PMP22 Gene Presents with Painful Peripheral Neuropathy and Varying Charcot-Marie-Tooth Features: A Case Series and Review of the Literature

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Kwo Wei David Ho ◽  
Nivedita U. Jerath
Keyword(s):  
Peripheral Neuropathy ◽  
Autosomal Recessive ◽  
Clinical Effect ◽  
Case Series ◽  
Pmp22 Gene ◽  
Loss Of Function ◽  
Review Of The Literature ◽  
Partial Loss ◽  
Charcot Marie Tooth ◽  
Electrophysiological Studies

The clinical effect of T118M variant of the PMP22 gene has been controversial. Several studies have suggested that it may be autosomal recessive, partial loss of function, or a benign variant. Here we report three cases in further support that the T118M variant of the PMP22 gene is a partial loss of function variant. These three unrelated cases were heterozygotes with the T118M variant of the PMP22 gene. All three cases presented with painful peripheral neuropathy and varying degrees of Charcot-Marie-Tooth exam features. Electrophysiological studies revealed polyneuropathy with axonal and demyelinating features in one case, but there were minimal electrophysiological changes in the other two cases. We propose that the T118M variant can cause painful peripheral neuropathy, which may be an underrecognized feature of this variant.

scholarly journals Heterogeneous presentation of caspr2 antibody‐associated peripheral neuropathy – A case series

2020 ◽  
Vol 24 (7) ◽  
pp. 1411-1418
Author(s):  
Erik Ellwardt ◽  
Christian Geber ◽  
Johannes Lotz ◽  
Frank Birklein
Keyword(s):  
Peripheral Neuropathy ◽  
Case Series

Immunosuppressive therapy of systemic lupus erythematosus associated peripheral neuropathy: A systematic review

Lupus ◽  
2020 ◽  
Vol 29 (12) ◽  
pp. 1509-1519
Author(s):  
Alexandru Constantin ◽  
Daniela Năstase ◽  
Delia Tulbă ◽  
Paul Bălănescu ◽  
Cristian Băicuș
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Peripheral Neuropathy ◽  
Lupus Erythematosus ◽  
Case Reports ◽  
Immunosuppressive Agents ◽  
Case Series ◽  
Systemic Lupus ◽  
Retrospective Case ◽  
Randomized Controlled ◽  
Neuropsychiatric Manifestations

Introduction Peripheral neurologic manifestations may be associated with most of the collagen vascular diseases including systemic lupus erythematosus (SLE), yet most of the times it is not clear what therapy should be prescribed. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations suggest the use of glucocorticoids and immunosuppressive agents for the treatment of SLE associated peripheral neuropathy (PN) (strength of statement A, category of evidence 1), however these recommendations are based on studies that did not focus specifically on PN but rather on neuropsychiatric manifestations of SLE out of which only one was a randomized controlled clinical trial that included 7 patients with peripheral neuropathy. The objective of this systematic review is to determine whether the pathogenic treatments (corticosteroids, immunosuppressive agents, intravenous immunoglobulins, plasmapheresis) are effective for SLE associated PN. Methods We searched MEDLINE for all the studies that included the pathogenic treatment of SLE associated PN. The purpose was to identify randomized clinical trials, and in the absence of these, we included observational studies and case reports or case series. Results The search returned only retrospective case reports or case series. Only one prospective study, a randomized controlled study, was focused on neuropsychiatric SLE and included few patients with PN (7). Some studies reported cases of PN responsive to glucocorticoids (GC), cyclophosphamide (CYC), rituximab (RTX), azathioprine (AZA), plasmapheresis (PPH), intravenous immunoglobulin (IVIG), mycophenolate mofetil (MMF) or different combinations of these immunosuppressive agents, whereas others noticed effectiveness of sequential treatments (i.e. administration of a therapeutic agent after another single agent or a combination of agents had previously failed). Many studies did not mention how the outcomes were objectively measured. Conclusions There are no interventional studies dedicated to the SLE associated PN, only retrospective case reports or case series which not only did they show contradictory results, but they also represent the lowest level of evidence. There is a strong need for new analytical studies dedicated to SLE associated PN. Protocol registered with PROSPERO (number CRD42019121748).

Hereditary sensory and autosomal peripheral neuropathy-type IV: case series and review of literature

2015 ◽  
Vol 19 (2) ◽  
pp. 117-123 ◽  
Author(s):  
D. P. Ashwin ◽  
G. D. Chandan ◽  
Handa Kaur Jasleen ◽  
G. C. Rajkumar ◽  
K. B. Rudresh ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Case Series ◽  
Review Of Literature ◽  
Type Iv

An exercise program for people with severe peripheral neuropathy and diabetic foot ulcers – a case series on feasibility and safety

2018 ◽  
Vol 42 (2) ◽  
pp. 183-189
Author(s):  
Kajsa Lindberg ◽  
Britt Sundekilde Møller ◽  
Klaus Kirketerp-Møller ◽  
Morten Tange Kristensen
Keyword(s):  
Peripheral Neuropathy ◽  
Diabetic Foot ◽  
Case Series ◽  
Exercise Program ◽  
Foot Ulcers ◽  
Diabetic Foot Ulcers

scholarly journals Acupuncture for the treatment of lower limb diabetic peripheral neuropathy: a systematic review

2019 ◽  
Vol 37 (1) ◽  
pp. 3-15 ◽  
Author(s):  
Jane Nash ◽  
Mike Armour ◽  
Stefania Penkala
Keyword(s):  
Peripheral Neuropathy ◽  
Outcome Measures ◽  
Data Extraction ◽  
Meta Analysis ◽  
Case Series ◽  
Acupuncture Point ◽  
Risk Of Bias ◽  
Point Selection ◽  
Local Point ◽  
Pain Symptoms

Objective: To examine evidence for acupuncture interventions in the management of diabetes-related peripheral neuropathy (DPN) symptoms. Methods: Five electronic databases were searched up to June 2017 for studies that included participants with symptoms of DPN, used an acupuncture intervention, and reported before-and-after DPN-related outcome measures. Two reviewers independently performed the data extraction. The level of homogeneity was assessed, and studies were appraised using the Cochrane Risk of Bias tool, the STRICTA guidelines for acupuncture reporting and the NICMAN scale for acupuncture quality. Results: Ten studies with 432 participants were included: three randomised controlled trials (RCTs), two pilot RCTs, three uncontrolled clinical trials, one quasi-RCT and one prospective case series. Improvements in DPN pain symptoms were reported by all studies. Heterogeneity of outcome measures prevented a meta-analysis. Variations were found in needle retention time and point selection, as well as total number and frequency of treatments. Common acupuncture point selections were ST36 and SP6. Half of the studies used local point selection. Studies conducted outside China had better acupuncture reporting and quality according to the STRICTA checklist and NICMAN scales, respectively. Risk of bias was high or unclear in the majority of studies for all domains except attrition bias. Conclusions: Acupuncture for DPN appears to improve symptoms. However, the application of acupuncture varies greatly, and the quality of included studies was generally low. Available studies have varying methodologies and different outcome measures. Further, suitably powered studies using appropriate DPN outcome measures are required.

Acupuncture Treatment for Chemotherapy-Induced Peripheral Neuropathy – a Case Series

2006 ◽  
Vol 24 (2) ◽  
pp. 87-91 ◽  
Author(s):  
Raimond Wong ◽  
Stephen Sagar
Keyword(s):  
Peripheral Neuropathy ◽  
Acupuncture Treatment ◽  
Clinical Course ◽  
Case Series ◽  
Current Management ◽  
Autonomic Nervous System Dysfunction ◽  
Neurophysiological Mechanisms ◽  
Prospective Case Series ◽  
Chemotherapy Agents

Chemotherapy induced peripheral neuropathy (CIPN) occurs in 10 to 20% of cancer patients treated with neurotoxic chemotherapy. A mixture of sensory, sensorimotor and autonomic nervous system dysfunction can occur, resulting in deterioration in function and worsened quality of life. A major feature is discomfort and pain. Early termination of treatment and dose reduction of chemotherapy may be necessary. The clinical course is variable and depends on the chemotherapy agents and their cumulative dose. Although symptoms can resolve completely, in most patients CIPN is either only partially reversible or completely irreversible. Current management for CIPN is symptomatic using membrane stabilising medications and antidepressants. The use of nerve growth factors is still experimental. Dysaesthesia and pain involving the feet and hands are described in both traditional Chinese medicine (TCM) and Western biomedicine. In TCM, the pathogenesis is related to the inability to direct Qi and Blood to the extremities, and is associated with Qi, Blood, Yang and Kidney deficiencies. Acupuncture is moderately effective in treating diabetic neuropathy. However, to date, there is no report of the usefulness of acupuncture for CIPN. We report the result of a pilot prospective case series of five patients treated with an acupuncture protocol that aims to correct Qi, Blood and Yang deficiencies and directs Qi and Blood to the extremities, with the goal of improving the symptoms of CIPN. The responses were encouraging, and cannot be easily explained by the known neurophysiological mechanisms of acupuncture.

Sign in / Sign up

Export Citation Format

Share Document